Long-term evaluation of neoadjuvant chemotherapy for breast cancer and influencing factors

HU Chen; JIA Zhilong; WEI Xiaochen; ZHU Liqin

PDF(885 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2020, Vol. 31 ›› Issue (3) : 224-228.

ORIGINAL ARTICLES

Long-term evaluation of neoadjuvant chemotherapy for breast cancer and influencing factors

HU Chen¹, JIA Zhilong², WEI Xiaochen¹, ZHU Liqin¹

Author information +

History +

Abstract

Objective To explore the influencing factors of the curative effect and prognosis of patients with breast cancer who have undergone neoadjuvant chemotherapy.Methods The clinicopathologic data on 190 locally advanced breast cancer patients receiving neoadjuvant chemotherapy was retrospectively collected and the factors that influenced pathologic complete response and prognosis of patients after neoadjuvant chemotherapy were analyzed.Results Among the 190 patients, 22 cases (11.58%) had pathological complete response after neoadjuvant chemotherapy. Univariate analysis showed that the expression level of ki-67, chemotherapy regimen and Luminal typing were correlated with PCR (P<0.05). Multivariate analysis showed that the expression level of ki-67 was an independent factor influencing the pathological complete response after neoadjuvant chemotherapy (P<0.05). The overall 10-year survival rate was 56.3%. Multivariate analysis showed that PCR was an independent factor affecting the survival rate of breast cancer patients after neoadjuvant chemotherapy (P<0.05).Conclusions Ki-67 is an independent factor that affects pathological complete response after neoadjuvant chemotherapy for breast cancer while PCR is an independent factor influencing the prognosis of breast cancer patients after neoadjuvant chemotherapy.

Key words

breast cancer / neoadjuvant chemotherapy / prognosis / Ki-67 / pCR

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

HU Chen, JIA Zhilong, WEI Xiaochen, ZHU Liqin. Long-term evaluation of neoadjuvant chemotherapy for breast cancer and influencing factors[J]. Medical Journal of the Chinese People Armed Police Forces. 2020, 31(3): 224-228

References

[1] Mcshane L M, Altman D G, Sauerbrei W, et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)[J]. J Natl Cancer Inst,2005,97(16):1180-1184.
[2] 沈镇宙,邵志敏. 乳腺肿瘤学[M].上海:上海科学技术出版社,2005.4:271.
[3] Rabanal C, Ruiz R, Neciosup S, et al. Metronomic chemotherapy for non-metastatic triple negative breast cancer: selection is the key[J]. World J Clin Oncol,2017,8(6):437-446.
[4] Elies A, Riviere S, Pouget N, et al. The role of neoadjuvant chemotherapy in ovarian cancer[J]. Expert Rev Anticancer Ther,2018,18(6):555-566.
[5] Yalcin B. Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy[J]. Exp Oncol,2013,35(4):250-252.
[6] Chen X S, Wu J Y, Huang O, et al. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy[J]. Oncol Rep,2010,23(5):1213-1220.
[7] Bernard A, William B,John B,et al.Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol,2018,19(1):27-39.
[8] Abubakar M, Orr N, Daley F, et al. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups[J]. Breast Cancer Res,2016,18(1):104.
[9] Ellis M J, Suman V J, Hoog J, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance)[J]. J Clin Oncol,2017,35(10):1061-1069.
[10] Ei B H, Zribi A, Laabidi S, et al. Ki-67: role in diagnosis, prognosis and follow-up after treatment of breast cancers[J]. Tunis Med,2015,93(12):737-741.
[11] Luporsi E, Andre F, Spyratos F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review[J]. Breast Cancer Res Treat,2012,132(3):895-915.
[12] Darwito D, Dharmana E, Riwanto I, et al. Effects of omega-3 supplementation on Ki-67 and VEGF expression levels and clinical outcomes of locally advanced breast cancer patients treated with neoadjuvant CAF chemotherapy: a randomized controlled trial report[J]. Asian Pac J Cancer Prev,2019,20(3):911-916.
[13] Tokuda E, Horimoto Y, Arakawa A, et al. Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer[J]. Hum Pathol,2017,63:40-45.
[14] 蒋奕,叶新青,黄俊淇,等. 乳腺癌新辅助化疗前后分子标记物变化及其与疗效的关系[J]. 广西医科大学学报,2015,32(2):211-215.
[15] 刘伟,李健斌,王涛,等. 蒽环类联合紫杉类方案在乳腺癌新辅助化疗中的有效性及安全性评价[J]. 临床肿瘤学杂志,2016,21(3):228-232.
[16] Luangdilok S, Samarnthai N, Korphaisarn K. Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients[J]. J Breast Cancer,2014,17(4):376-385.
[17] Wu K, Yang Q, Liu Y, et al. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy[J]. World J Surg Oncol,2014,12:95.
[18] Chaudhary L N, Wilkinson K H, Kong A. Triple-negative breast cancer: who should receive neoadjuvant chemotherapy?[J]. Surg Oncol Clin N Am,2018,27(1):141-153.
[19] Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours[J]. Nature,2000,406(6797):747-752.
[20] Cazzaniga M E, Pinotti G, Montagna E, et al. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: final results of the VICTOR-6 study[J]. Breast,2019,48:7-16.